C4 Therapeutics, Inc. (CCCC)

Over the past six months, C4 Therapeutics, Inc.'s stock price has been influenced by several events. The company reported its Third Quarter 2025 financial results on November 6, 2025, which included a net loss of $0.44 per share, beating the consensus estimate, and revenues of $11.23 million, surpassing expectations. Despite beating revenue estimates, the company's shares have experienced a significant decrease of approximately 38.11% to 43.84% over the last year. In October 2025, C4 Therapeutics announced the pricing of a $125 million underwritten offering and entered into a clinical trial collaboration with Pfizer for Cemsidomide and Elranatamab. C4 Therapeutics also participated in the 8th Annual Evercore Healthcare Conference in late November and early December 2025. Earlier in the year, the company highlighted progress in its degrader portfolio, including promising Phase 1 results for cemsidomide in multiple myeloma and non-Hodgkin lymphoma, and reported its Q4 and full-year 2024 financial results.

As a clinical-stage biopharmaceutical company, C4 Therapeutics, Inc.'s demand does not exhibit typical seasonality. The company's revenue is primarily derived from collaboration agreements, and its pipeline products are in various stages of clinical development. Demand is driven by clinical trial progress, regulatory milestones, and partnership developments rather than seasonal consumer patterns.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted protein degraders within the Healthcare sector, specifically in Biotechnology and Pharmaceutical Products. The company aims to create medicines by using the body's protein disposal machinery to eliminate disease-causing proteins, targeting oncology and immuno-oncology indications. C4 Therapeutics utilizes its CiD and TORPEDO platforms to design and optimize small-molecule degrader candidates, with lead product candidates like Cemsidomide, CFT1946, and CFT8919 in preclinical and clinical stages. The company has collaborations with major pharmaceutical partners such as F. Hoffmann-La Roche Ltd, Biogen MA, Inc., Betta Pharmaceuticals Co., Ltd., Merck KGaA, Merck Sharp & Dohme, LLC, and Calico Life Sciences LLC.

C4 Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States. The company operates research laboratories within the United States and collaborates with academic institutions and contract research organizations globally.

C4 Therapeutics has maintained a "Hold" consensus rating from Wall Street analysts in the past year, with some analysts issuing "buy" ratings. The company's reputation is primarily tied to its scientific advancements and clinical pipeline progress in targeted protein degradation. Positive developments in its clinical trials, such as promising data for cemsidomide in multiple myeloma, contribute to its scientific standing.

C4 Therapeutics, Inc. has a mixed ownership structure, with a significant portion held by institutional investors. Approximately 78.81% of the stock is held by institutions, including major holders like Orbimed Advisors LLC, Wasatch Advisors LP, Vanguard Group Inc., Bank of America Corp DE, Lynx1 Capital Management LP, Soleus Capital Management, L.P., Morgan Stanley, Millennium Management Llc, and BlackRock, Inc. The largest individual shareholder is Marc A. Cohen, owning 8.31 million shares, representing 8.57% of the company.